Advertisement

Advertisement

ESMO World Congress on Gastrointestinal Cancer 2020 Virtual

Pancreatic Cancer

First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer

In patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma, treatment with liposomal irinotecan plus fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) resulte...

Hepatobiliary Cancer

ESMO World GI: Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions

At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast grow...

Hepatobiliary Cancer

Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions

At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast grow...

Pancreatic Cancer

Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Pancreatic Cancer Across Age Groups: Additional Analysis of the POLO Trial

According to an additional analysis from the POLO trial, safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent, irrespec...

Advertisement

Advertisement



Advertisement